(¿Â¶óÀÎ) 2020 ´ëÇÑ°£ÇÐȸ Áö¹æ°£¿¬±¸È¸ NAFLD ½ÉÆ÷Áö¾ö : 2020-10-24±³À°ÀÏÀÚ : 2020-10-24
±³À°Àå¼Ò : ¿Â¶óÀÎ ±³À°
±³À°ÁÖÁ¦ :
(¿Â¶óÀÎ) 2020 ´ëÇÑ°£ÇÐȸ Áö¹æ°£¿¬±¸È¸ NAFLD ½ÉÆ÷Áö¾ö ÁÖÃÖ±â°ü : ´ëÇÑ°£ÇÐȸ
½ÃÇà±â°ü(ÁöºÎ/°ú) : ´ëÇÑÁö¹æ°£¿¬±¸È¸
´ã´çÀÚ : Áغñ»ç¹«±¹
¿¬¶ôó : 02-373-1005
À̸ÞÀÏ :
kaslsymposium@hbni.co.kr ±³À°Á¾·ù : ³»°ú
Âü¼®¿¹»óÀοø : 300¸í
Èñ¸ÁÆòÁ¡ : 6Á¡
Áö¿ª :
¼¿ïƯº°½Ã±³À°½Ã°£ : 6 ½Ã°£ 15ºÐ
¼¼ºÎ¼ö°·á : 40,000¿ø
ºñ°í ȸ¿ø,ÀüÀÓÀÇ,Àü°øÀÇ 3¸¸¿ø, ºñȸ¿ø 4¸¸¿ø
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±âŸ 10¿ù 24ÀÏ ¿Â¶óÀÎ 08:50~08:55 Opening Remark ÀÌÁø¿ì(Áö¹æ°£¿¬±¸È¸ ȸÀå)
±âŸ 10¿ù 24ÀÏ ¿Â¶óÀÎ 08:55~09:00 Congratulatory Remark ÀÌÇÑÁÖ(´ëÇÑ°£ÇÐȸ ÀÌ»çÀå)
±³À°½Ã°£ 10¿ù 24ÀÏ ¿Â¶óÀÎ 09:00~09:25 Metabolic Dysfunction Associated Fatty Liver: Better Definition? Vincent Wong(The Chinese Univ. of Hong Kong Hong Kong)
±³À°½Ã°£ 10¿ù 24ÀÏ ¿Â¶óÀÎ 09:25~09:50 Natural Course: How Can We Change? ±è»ó±Õ(¼øõÇâÀÇ´ë)
±³À°½Ã°£ 10¿ù 24ÀÏ ¿Â¶óÀÎ 09:50~10:15 Lean NAFLD: Better or Worse than Obese NAFLD? ±èÈÖ¿µ(ÀÌÈÀÇ´ë)
ÈÞ½Ä 10¿ù 24ÀÏ ¿Â¶óÀÎ 10:15~10:25 Break ()
±³À°½Ã°£ 10¿ù 24ÀÏ ¿Â¶óÀÎ 10:25~10:50 Screening: Who and When by Which Tools? ÀÌÇý¿ø(¿¬¼¼ÀÇ´ë)
±³À°½Ã°£ 10¿ù 24ÀÏ ¿Â¶óÀÎ 10:50~11:15 Biochemical/Equation Biomarkers ±è½Â¾÷(¿¬¼¼ÀÇ´ë)
±³À°½Ã°£ 10¿ù 24ÀÏ ¿Â¶óÀÎ 11:15~11:40 Imaging Biomarkers ÃÖÁØÀÏ(°¡Å縯ÀÇ´ë)
±³À°½Ã°£ 10¿ù 24ÀÏ ¿Â¶óÀÎ 11:40~12:05 Omics ±è¿ø(¼¿ïÀÇ´ë)
½Ä»ç 10¿ù 24ÀÏ ¿Â¶óÀÎ 12:05~12:40 Lunch ()
±³À°½Ã°£ 10¿ù 24ÀÏ ¿Â¶óÀÎ 12:40~13:05 Effective Referrals: The Role of Pimary Care Physicians ¼Ûµµ¼±(°¡Å縯ÀÇ´ë)
±³À°½Ã°£ 10¿ù 24ÀÏ ¿Â¶óÀÎ 13:05~13:30 Exercise with Diet and Alcohol Àü´ë¿ø(ÇѾçÀÇ´ë)
±³À°½Ã°£ 10¿ù 24ÀÏ ¿Â¶óÀÎ 13:30~13:55 Pharmacological Treatment: Now and Future Yoshio Sumida(Aichi Medical Univ. Japan)
±³À°½Ã°£ 10¿ù 24ÀÏ ¿Â¶óÀÎ 13:55~14:20 Monitoring and Outcome Assessment: How and When by Which Tools? ±è¹®¿µ(¿¬¼¼¿øÁÖÀÇ´ë)
ÈÞ½Ä 10¿ù 24ÀÏ ¿Â¶óÀÎ 14:20~14:30 Break ()
±³À°½Ã°£ 10¿ù 24ÀÏ ¿Â¶óÀÎ 14:30~14:55 Insulin Resistance: Repositioning of Anti-Diabetics ÀÌÁ¤ÀÏ(¿¬¼¼ÀÇ´ë)
±³À°½Ã°£ 10¿ù 24ÀÏ ¿Â¶óÀÎ 14:55~15:20 Cardiovascular Risk: Repositioning of Anti-Lipids À庴±¹(°è¸íÀÇ´ë)
±³À°½Ã°£ 10¿ù 24ÀÏ ¿Â¶óÀÎ 15:20~15:45 Oncologic Risk: Assessment and Surveillance ¼¿¬¼®(°í·ÁÀÇ´ë)
±³À°½Ã°£ 10¿ù 24ÀÏ ¿Â¶óÀÎ 15:45~16:10 Beyond Medical Intervention ÀÌ¿µ¼±(°í·ÁÀÇ´ë)
±âŸ 10¿ù 24ÀÏ ¿Â¶óÀÎ 16:10~16:15 Closing Remark ±è½Â¾÷(Áö¹æ°£¿¬±¸È¸ ÇмúÀÌ»ç)